DBVT

DBV Technologies S.A. DBVT

NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,923 of 2,925

Why it scores 4Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$700.0K

Quarter to Jun 30

Net income

$-50.40M

Quarter to Jun 30

Free cash flow

$-53.00M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$345.69M total
MPM BioImpact LLC
$60.13M-29.7%
Siren, L.L.C.
$30.46M0.0%
Vivo Capital, LLC
$30.25M-30.8%
PERCEPTIVE ADVISORS LLC
$27.11M+71.4%
BAKER BROS. ADVISORS LP
$23.97M0.0%
Artisan Partners Limited Partnership
$22.51M-38.1%
UBS Group AG
$21.54M+1551.4%
MORGAN STANLEY
$15.66M+553.5%
Logos Global Management LP
$15.01MNew
Patient Square Capital LP
$14.92M+31.1%
Octagon Capital Advisors LP
$9.42M0.0%
ADAR1 Capital Management, LLC
$8.66M-47.8%
Redmile Group, LLC
$6.73M-16.5%
Duquesne Family Office LLC
$6.29M0.0%
AMERIPRISE FINANCIAL INC
$6.21M+63.6%
MILLENNIUM MANAGEMENT LLC
$4.39M-16.0%
Elmind Capital, LP
$4.35M0.0%
JANE STREET GROUP, LLC
$3.67M+1884.2%
Ishara Investments LP
$3.03M+80.0%
Yiheng Capital Management, L.P.
$2.79M0.0%
BOOTHBAY FUND MANAGEMENT, LLC
$2.68M0.0%
GREAT POINT PARTNERS LLC
$2.57MNew
HRT FINANCIAL LP
$2.48M+527.8%
NEW YORK STATE COMMON RETIREMENT FUND
$1.96M-29.0%
ENVESTNET ASSET MANAGEMENT INC
$1.87M+18.9%
See all 78 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DBVT

Earnings Per Share

13fpro.ai/company/DBVT

Loading ratio trend…

DBVT key financials by period

Reported revenue, net income and operating margin by fiscal year, from DBV Technologies S.A.'s annual filings on SEC EDGAR.

DBV Technologies S.A. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$5.6M$-146.9M—
FY 2024$4.2M$113.9M—
FY 2023$15.7M$72.7M—
FY 2022$4.8M$96.3M—
FY 2021$5.7M$-97.8M—
FY 2020$11.3M$-159.6M—
Source: DBVT filings on SEC EDGAR →

Companies similar to DBVT

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

DBVT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About DBV Technologies S.A. (DBVT): stock profile, AI score and financials

DBV Technologies S.A. (DBVT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DBVT at 3.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,923 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), DBV Technologies S.A. reports quarterly revenue of $700.0K, net income of $-50.4M, free cash flow of $-53.0M. Top institutional holders of DBVT by reported 13-F value include MPM BioImpact, Siren, L.L.C., Vivo Capital, based on the most recent SEC filings. DBVT trades on the Nasdaq exchange and files with the SEC under CIK 1613780. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DBVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DBV Technologies S.A. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1613780 →